Glioma targeted therapy: insight into future of molecular approaches

K Yang, Z Wu, H Zhang, N Zhang, W Wu, Z Wang… - Molecular Cancer, 2022 - Springer
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Tumor angiogenesis: causes, consequences, challenges and opportunities

R Lugano, M Ramachandran, A Dimberg - Cellular and Molecular Life …, 2020 - Springer
Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

The blood–brain barrier and blood–tumour barrier in brain tumours and metastases

CD Arvanitis, GB Ferraro, RK Jain - Nature Reviews Cancer, 2020 - nature.com
For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

W Wu, JL Klockow, M Zhang, F Lafortune… - Pharmacological …, 2021 - Elsevier
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

The use of alternative strategies for enhanced nanoparticle delivery to solid tumors

M Izci, C Maksoudian, BB Manshian… - Chemical …, 2021 - ACS Publications
Nanomaterial (NM) delivery to solid tumors has been the focus of intense research for over a
decade. Classically, scientists have tried to improve NM delivery by employing passive or …

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

JD Martin, H Cabral, T Stylianopoulos… - Nature reviews Clinical …, 2020 - nature.com
Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia

RK Jain - Cancer cell, 2014 - cell.com
Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment.
However, these agents, intended to block tumors' blood supply, may cause hypoxia, which …

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

S Venneti, AR Kawakibi, S Ji, SM Waszak, SR Sweha… - Cancer discovery, 2023 - AACR
Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven
effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the …

Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy

SA Patel, MB Nilsson, X Le, T Cascone, RK Jain… - Clinical Cancer …, 2023 - AACR
Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known
mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation …

Targeting the tumour vasculature: from vessel destruction to promotion

S Guelfi, K Hodivala-Dilke, G Bergers - Nature Reviews Cancer, 2024 - nature.com
As angiogenesis was recognized as a core hallmark of cancer growth and survival, several
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …